Delivering final compounds fast and efficiently to our customers is essential to help drive projects to meet key project milestones. To this end, BioAscent has invested in two new ACCQPrep HP150 preparative HPLC instruments. The HPLC systems that have been acquired are linked to Purlon mass spectrometers and 2x2 AutoSampler modules enabling automated mass directed purification of both final compounds and late-stage intermediates.
As BioAscent continues to grow, the ACCQPrep HP150 systems enhance existing preparative HPLC capabilities enabling the chemistry team to deliver target molecules more rapidly and efficiently and to the high levels of purity that our clients expect.
Euan Fordyce, Group Leader at BioAscent, says: “The systems, which were fully installed in January, are already being used on various BioAscent projects by our chemists who have extensive experience in HPLC purification. We continue to invest in the best technology and having this additional capacity adds value to the service we can offer to our customers.”
Josh Lovell, Product Line Manager (Pharma R&D Products) at Teledyne ISCO, says: “Since its release six years ago, the ACCQPrep HP150 has become a go-to choice for chemists across the world with its reputation to deliver purification results with reliability and ease-of-use. Teledyne ISCO values the trust that BioAscent places in us and our instruments to achieve the purification needs their customers demand by being the first CRO in the UK with multiple ACCQPrep HP150 preparative HPLC instruments able to perform mass-directed purifications. As BioAscent’s success continues we are excited to continue to meet their growing flash and preparative HPLC needs.”
The investment in this state-of-the-art equipment is part of a wider strategy to grow the chemistry group's automated purification capabilities and has seen an increase in flash chromatography capabilities through the purchase of two new CombiFlash NextGen 300+ systems and two new GeneVac EZ-2 Elite benchtop evaporators.
To find out more about BioAscent’s comprehensive medicinal and synthetic chemistry expertise, click here.